Abcl stock forecast.

ABCL | Complete AbCellera Biologics Inc. stock news by MarketWatch. View real-time stock prices and stock quotes for a full financial overview.

Abcl stock forecast. Things To Know About Abcl stock forecast.

Long-term ABCL price forecast for 2025, 2030, 2035, 2040, 2045 and 2050. Our analysts are offering long term price forecasts for AbCellera Biologics Inc In 2050, the median target price for ABCL is $317.20, with a high estimate of $352.81 and a low estimate of $30.87. The median estimate represents a +6,902% increase from the last price of $4. ... Bitfarms Ltd () Stock Market info Recommendations: Buy or sell Bitfarms stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Bitfarms share forecasts, stock quote and buy / sell signals below.According to present data Bitfarms's BITF shares and potentially its market environment have been in a bullish cycle in the …15 sept 2023 ... ... . ABCELLERA stock analysis ABCELLERA stock news ABCELLERA stock forecast ABCELLERA stock buy or sell ABCELLERA stock investment advice ABCELLERA ...The above table shows the analyst ABCL forecast and predictions for the stock price in 12 month’s time. Date Share Price Average 1Y Price Target Dispersion High Low 1Y Actual price Analysts; Current: US$4.83

Get the latest AbCellera Biologics Inc (ABCL) real-time quote, historical performance, charts, and other financial information to help you make more informed trading and investment decisions. Nov 28, 2023 · ABCL stock forecast for 2023 – 2027. Last updated: October 5, 2023. ABCL. AbCellera Biologics Inc. 4.43 D 1.14% (0.05) Are you interested in AbCellera Biologics Inc. stocks prediction? If yes, then on this page you will find useful information about the dynamics of the ABCL stock price in 2022-2027. Is ABCL a good long term stock? When should ...

According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price.Find the latest Institutional Holdings data for AbCellera Biologics Inc. Common Shares (ABCL) at Nasdaq.com.

AbCellera Biologics (NASDAQ:ABCL) First Quarter 2023 ResultsKey Financial Results. Revenue: US$12.2m (down 96% from 1Q 2022). Net loss: US$40.1m (down by 124% from US$168.6m profit in 1Q 2022).The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is 10.10 - 35.70 USD. Based on the ratings of 15, the consensus recommendation for ABCL is BUYAbCellera Biologics (ABCL) Stock Forecast & Price Target $4.43 0.00 (0.00%) (As of 11/24/2023 ET) Compare Today's Range $4.40 $4.49 50-Day Range $3.91 $5.13 52 …May 26, 2023 · ABCL Stock Performance: A Look at May 26, 2023. On May 26, 2023, Abcellera Biologics Inc (ABCL) saw a significant increase in its stock price, with shares trading at $28.00, up 306.39% from the previous day’s closing price. This surge in price can be attributed to the positive outlook of the 9 analysts who offer 12-month price forecasts for ABCL.

The average stock forecast for Abcellera Biologics Inc (ABCL) is 22.44 USD. This price target corresponds to an upside of 364.60%. The range of stock forecasts for ABCL is …

Find the latest AbCellera (NASDAQ: ABCL) stock information.

Find the latest Bionano Genomics, Inc. (BNGO) stock quote, history, news and other vital information to help you with your stock trading and investing.Stock Price Forecast. According to 6 stock analysts, the average 12-month stock price forecast for ABCL stock stock is $22.33, which predicts an increase of …5 abr 2023 ... Their average price target stands at $19, implying 266% upside potential. AbCellera Biologics (ABCL). Pipette adding fluid to one of several ...Analyst Forecast. According to 7 analysts, the average rating for ABCL stock is "Strong Buy." The 12-month stock price forecast is $22.33, which is an …25 sept 2023 ... AbCellera Stock Analysis | Why ABCL Stock is Falling. Nanalyze•4.5K ... | AAPL Stock Analysis | Apple Stock Price Prediction. Parkev Tatevosian ...

Abcellera Biologics Inc (NASDAQ:ABCL) 4.76 Delayed Data As of 3:59pm ET +0.035 / +0.74% Today’s Change 3.87 Today ||| 52-Week Range 14.00 -52.96% Year-to-Date Quote Profile News Charts...AbCellera Biologics Stock Chart and Share Price Forecast, Short-Term "ABCL" Stock Prediction for Next Days and Weeks Walletinvestor.com AbCellera Biologics Inc (ABCL) Forecast Chart, Long-Term Predictions for Next Months and Year: 2023, 2024 According to our current ABC stock forecast, the value of AmerisourceBergen shares will rise by 0.00% and reach $ 179.98 per share by November 22, 2023. According to our technical indicators, the current …James O'Neil/DigitalVision via Getty Images. AbCellera Biologics ( NASDAQ: ABCL) to date has been quite a lousy investment. From the IPO high of $58.90, all the way down to the current price of ...Nov 29, 2023 · According to 40 analysts, the average rating for MSFT stock is "Strong Buy." The 12-month stock price forecast is $392.0, which is an increase of 3.51% from the latest price. 6.7900. 6.7900. 2,102,000. *Close price adjusted for splits. **Adjusted close price adjusted for splits and dividend and/or capital gain distributions. Loading more data... Discover historical prices for ABCL stock on Yahoo Finance. View daily, weekly or monthly format back to when AbCellera Biologics Inc. stock was issued.

10 equities research analysts have issued twelve-month target prices for AbCellera Biologics' stock. Their ABCL share price …

ABCL Stock Performance on October 13, 2023: Overview, Analysis, and Projections. ABCL Stock Performance on October 13, 2023: – Previous close on October 12, 2023: $4.39 – Opening price on October 13, 2023: $4.41 – Range of fluctuation: $3.92 to $4.41 – Trading volume on October 13, 2023: 4,206,194 sharesPrevious Close $4.4. Volume 1.91M. Average Volume (3M) 1.64M. Market Cap. $1.28B. Enterprise Value $1.28B. Total Cash (Recent Filing) $795.69K. Total Debt (Recent Filing) $84.03K. Price to Earnings (P/E) -9.8.1 Month Ago. -$0.12. 3 Months Ago. -$0.14. AbCellera Biologics Inc. analyst estimates, including ABCL earnings per share estimates and analyst recommendations.What happened. Shares of AbCellera Biologics (ABCL 2.55%) fell 21.6% in October, according to data from S&P Global Market Intelligence.The biotech declined in response to news that an experimental ...What is AbCellera Biologics Inc. (ABCL) stock EPS forecast? AbCellera Biologics Inc. beat analysts’ expectations during the last earnings period by -28.57%. AbCellera Biologics Inc. reported earnings of -$ 0.10 per share on Nov 2, 2023, while the forecasted EPS was -$ 0.14. Market Closed. ABCL. AbCellera Biologics.ABCL - Cup & Handle Breakout Trade Abcellera Biologics is a biotech stock setting up in a textbook cup with handle pattern. The stock has growing institutional sponsorship as shown in the chart from MarketSmith on the chart. It also has a relative strength ranking of 97/100. Shares formed a cup with a 37% depth and have since driftAbcellera ...

Throughout the U.S., the weather can be quite unpredictable, even with state-of-the-art radar, sensors and computer modeling technology right at meteorologists’ fingertips. The Old Farmer’s Almanac first provided valuable statistics and dat...

Find the latest AbCellera Biologics Inc. ABCL analyst stock forecast, price target, and recommendation trends with in-depth analysis from research reports. Date Range. investment rating.

According to 14 stock analysts, the average 12-month stock price forecast for Palantir stock is $13.25, which predicts a decrease of -34.63%. The lowest target is $5.00 and the highest is $25. On average, analysts rate Palantir stock as a hold.AbCellera Biologics Inc. reported earnings of -$ 0.10 per ABCL share on Nov 2, 2023. AbCellera Biologics Inc. fell short of analysts' expectations by -28.57%. Meanwhile, the company posted an EPS of -$ 0.12 last year, which is a -193.33% lower compared to the same period last year. Report Date. Nov 2, 2023.Insiders purchased significant amount of AbCellera stock directly after Q1. See why I ABCL shares are increasingly attractive for long-term, patient investors.15 sept 2023 ... My next multi bagger stock is Abcellera Biologics - stock symbol: ABCL. Victor H Investing•528 views · 12:08 · Go to channel · Community is ...Lilly(Eli) & Co () Stock Market info Recommendations: Buy or sell Lilly(Eli) stock? Wall Street Stock Market & Finance report, prediction for the future: You'll find the Lilly(Eli) share forecasts, stock quote and buy / sell signals below.According to present data Lilly(Eli) 's LLY shares and potentially its market environment have been in a bullish cycle in the last …AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -1,100% and 62.63%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for ...AbCellera Biologics Inc. analyst ratings, historical stock prices, earnings estimates & actuals. ABCL updated stock price target summary. Long-term ACB price forecast for 2025, 2030, 2035, 2040, 2045 and 2050. Our analysts are offering long term price forecasts for Aurora Cannabis Inc. In 2050, the median target price for ACB is $ 38.03, with a high estimate of $ 80.99 and a low estimate of $ 14.32. The median estimate represents a +8166.35% increase from the last price of $ 0.4601.For AMERISOURCEBERGEN CORP stock forecast for 2023, 2 predictions are offered for each month of 2023 with average AMERISOURCEBERGEN CORP stock forecast of $186.62, a high forecast of $187.17, and a low forecast of $186.07. The average AMERISOURCEBERGEN CORP stock forecast 2023 represents a -0.54% decrease …Dec 1, 2023 · Analyst Forecast. According to 41 analysts, the average rating for NVDA stock is "Strong Buy." The 12-month stock price forecast is $609.89, which is an increase of 30.42% from the latest price.

According to analyst projections, ABCL’s forecast low is $10.00 with $34.00 as the target high. To hit the forecast high, the stock’s price needs a -639.13% plunge from its current level, while the stock would need to soar -117.39% for it to hit the projected low. AbCellera Biologics Inc (ABCL) estimates and forecastsStock Price Forecast. The 1 analysts offering 12-month price forecasts for Microbot Medical Inc have a median target of 8.00, with a high estimate of 8.00 and a low estimate of 8.00. The median ...According to . 3 Wall Street analysts that have issued a 1 year ABCL price target, the average ABCL price target is $18.67, with the highest ABCL stock price forecast at $24.00 and the lowest ABCL stock price forecast at $12.00. Their ACN share price targets range from $279.00 to $410.00. On average, they anticipate the company's stock price to reach $337.26 in the next year. This suggests that the stock has a possible downside of 0.2%. View analysts price targets for ACN or view top-rated stocks among Wall Street analysts.Instagram:https://instagram. 7 11 stockpre ipo investing platformsccne stock pricestock ninja Jan 5, 2023 · A $14.3 billion market cap divided by 330 million shares outstanding equals a valuation of $43.33 per share. Discounting a year 2030, $43.33 valuation, using a 10% discount rate gives us a present ... co ccuan stock dividend Whether it is the stock market, housing market, or livestock market, when confidence leaves it can have a big impact on prices. Cattle Australia deputy chair Garry … rinc stock About the AbCellera Biologics Inc stock forecast. As of 2023 November 28, Tuesday current price of ABCL stock is 4.530$ and our data indicates that the asset price has been in a downtrend for the past 1 year (or since its inception).View AbCellera Biologics Inc ABCL investment & stock information. Get the latest AbCellera Biologics Inc ABCL detailed stock quotes, stock data, Real-Time ECN, charts, stats and more.Abcellera Biologics Inc (ABCL) Company Description. AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.